Literature DB >> 6848703

Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice.

R T Proffitt, L E Williams, C A Presant, G W Tin, J A Uliana, R C Gamble, J D Baldeschwieler.   

Abstract

EMT6 tumors in BALB/c mice have been successfully imaged with small (less than 0.1 mu), unilamellar lipid vesicles (SUVs) loaded with In-111 nitrilotriacetic acid (In-111 NTA). Neutral SUVs prepared from distearoyl phosphatidylcholine (DSPC) and cholesterol (CH) (ratio 2:1) delivered sufficient radioactivity to allow tumor visualization 24 hr after i.v. injection; so did positively and negatively charged SUVs with the ratio 4:1:1 for DSPC:CH:X, were X was stearylamine or dicetyl phosphate. Other SUVs containing a 6-aminomannose or 6-aminomannitol derivative of cholesterol did not cause significant tumor accumulation of In-111 NTA, and tumor images were not readily discernible. The maximum tumor-associated radioactivity, 18.5% of injected dose per gram of tissue, was achieved with neutral SUVs. This level of tumor-associated In-111 was over 4 times that observed when unencapsulated In-111 NTA was injected. Neutral SUVs also gave the lowest specific activities in the liver and spleen (14.6% and 18.8% of dose respectively).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848703

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

Review 1.  Nanosystems for simultaneous imaging and drug delivery to T cells.

Authors:  Tarek M Fahmy; Peter M Fong; Jason Park; Todd Constable; W Mark Saltzman
Journal:  AAPS J       Date:  2007-06-08       Impact factor: 4.009

2.  Low density lipoprotein receptor-independent hepatic uptake of a synthetic, cholesterol-scavenging lipoprotein: implications for the treatment of receptor-deficient atherosclerosis.

Authors:  K J Williams; S Vallabhajosula; I U Rahman; T M Donnelly; T S Parker; M Weinrauch; S J Goldsmith
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

Review 3.  The use of liposomes in the diagnosis and treatment of malignant disease.

Authors:  I Levy; J Roberts; M Baum
Journal:  Postgrad Med J       Date:  1987-10       Impact factor: 2.401

Review 4.  Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Authors:  John C Kraft; Jennifer P Freeling; Ziyao Wang; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

Review 5.  Challenges in development of targeted liposomal therapeutics.

Authors:  Rupa R Sawant; Vladimir P Torchilin
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

6.  Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice.

Authors:  M B Bally; D Masin; R Nayar; P R Cullis; L D Mayer
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Indium-111-labelled liposomes: dosimetry and tumour detection in patients with cancer.

Authors:  A Kubo; K Nakamura; T Sammiya; M Katayama; T Hashimoto; S Hashimoto; H Kobayashi; T Teramoto
Journal:  Eur J Nucl Med       Date:  1993-02

Review 8.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

9.  Model studies directed toward the boron neutron-capture therapy of cancer: boron delivery to murine tumors with liposomes.

Authors:  K Shelly; D A Feakes; M F Hawthorne; P G Schmidt; T A Krisch; W F Bauer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

10.  11C-coenzyme Q10: a new myocardial imaging tracer for positron emission tomography.

Authors:  K Ishiwata; Y Miura; T Takahashi; K Kawashima; K Yanai; M Monma; T Ido
Journal:  Eur J Nucl Med       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.